# ZEGFROVY (Sunvozertinib) by Dizal Pharmaceutical Co., Ltd.: new human prescription drug listing

**Launch Signal Score:** 70/100

| Field | Value |
|---|---|
| Product | ZEGFROVY |
| Generic name | Sunvozertinib |
| NDC | 84694-101 |
| Labeler | Dizal Pharmaceutical Co., Ltd. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Approval pathway | NDA |
| Application number | NDA219839 |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Active ingredients | SUNVOZERTINIB 150 mg/1 |
| Marketing start | 2026-10-22 |
| Package configurations | 1 |

## Why this score
- Prescription or biologic product.
- Brand or biologic launch.

Source: U.S. FDA National Drug Code (NDC) Directory via openFDA (https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=84694-101). Last refreshed: 2026-11-04T18:12:05.743Z.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.